Griffin Securities Analyst Thinks New MannKind Management Will Focus On R&D, Not Sanofi Merger

By: via Benzinga
Speaking to Benzinga, Griffin Securities Analyst Dr. Keith Markey said that after MannKind Corporation (NASDAQ: MNKD) founder Alfred ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.